DBV Technologies Announces Filing of 2015 "Document de Référence" and 2015 Annual Report on Form 20-F
(Thomson Reuters ONE) -
Press Release
Montrouge, France, April 28, 2016
DBV Technologies Announces Filing of 2015 "Document de Référence" and 2015
Annual Report on Form 20-F
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), a clinical-stage specialty biopharmaceutical company, today announced the
filing of its 2015 Annual Report "Document de Référence" for the year ended
December 31, 2015 with the French market authority "Autorité des Marchés
Financiers" (AMF) and the filing of its Annual Report on Form 20-F for the year
ended December 31, 2015 with the U.S. Securities and Exchange Commission (SEC).
These documents can be accessed on the Investor Relations section of the
Company's website at www.dbv-technologies.com. In addition, the "Document de
Référence" is available on the AMF's website at www.amf-france.org and the Form
20-F is available on the SEC's website at www.sec.gov. Printed copies of the
"Document de Référence" are available at the Company's headquarters and
registered office located at 177-181 avenue Pierre Brossolette 92120 Montrouge,
France. Any shareholder can request a printed copy of the Form 20-F, free of
charge, upon request. Requests should be directed to DBV Technologies, Attn:
Investor Relations, 177-181 avenue Pierre Brossolette 92120 Montrouge, France.
About DBV Technologies
DBV Technologies developed Viaskin®, a proprietary technology platform with
broad potential applications in immunotherapy. Viaskin is based on epicutaneous
immunotherapy, or EPIT®, DBV's method of delivering biologically active
compounds to the immune system through intact skin. With this new class of self-
administered and non-invasive product candidates, the company is dedicated to
safely transforming the care of food allergic patients, for whom there are no
approved treatments. DBV's food allergies programs include ongoing clinical
trials of Viaskin Peanut and Viaskin Milk, and preclinical development of
Viaskin Egg. DBV is also pursuing a human proof concept clinical study of
Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring
potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, New
York. Company shares are traded on segment B of Euronext Paris (Ticker: DBV,
ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq
Global Select Market in the form of American Depositary Shares (each
representing one-half of one ordinary share) (Ticker: DBVT). For more
information on DBV Technologies, please visit our website at www.dbv-
technologies.com.
DBV Technologies Contact
Susanna Mesa
Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa(at)dbv-technologies.com
Media Contacts
Erinn White, Centron PR
+1 646-722-8822
ewhite(at)centronpr.com
Marion Janic, Rooney & Associates
+1 212-223-4017
mjanic(at)rooneyco.com
Media Contacts, Europe
Caroline Carmagnol, Alize RP - Relation Presse
+33 (0)6 64 18 99 59
caroline(at)alizerp.com
20F:
http://hugin.info/156437/R/2008215/742700.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DBV Technologies via GlobeNewswire
[HUG#2008215]
Unternehmensinformation / Kurzprofil:
Datum: 28.04.2016 - 23:30 Uhr
Sprache: Deutsch
News-ID 467429
Anzahl Zeichen: 4323
contact information:
Town:
Bagneux
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 191 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DBV Technologies Announces Filing of 2015 "Document de Référence" and 2015 Annual Report on Form 20-F"
steht unter der journalistisch-redaktionellen Verantwortung von
DBV Technologies (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
